BACKGROUND AND OBJECTIVES: Hyperphosphatemia and subclinical endotoxemia are important sources of inflammation in HD. Proinflammatory cytokines are strong correlates of soluble CD14 (sCD14) concentrations, an independent predictor of mortality in this population. We evaluated the effects of calcium acetate and sevelamer hydrochloride on serum inflammatory profile, endotoxin concentrations, and sCD14 levels in HD patients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Prospective, randomized, open-label, parallel design trial. Fifty-nine stable HD patients, 30 receiving sevelamer, and 29 receivingcalcium acetate were evaluated. Serum levels of inflammatory parameters (high-sensitivity C-reactive protein [hs-CRP], TNF-α, interleukin (IL)-1, -6, -10, and -18), as well as endotoxin and sCD14 concentrations, were measured at baseline and after 3 months of therapy. RESULTS:Serum IL-6 increased in patients receiving calcium acetate, whereas hs-CRP and IL-6 significantly decreased in subjects treated with sevelamer, with IL-10 experiencing a trend to increase (P = 0.052). Serum endotoxin and sCD14 levels did not change after treatment with calcium acetate. However, these parameters decreased by 22.6% and 15.2%, respectively (P < 0.01), in patients receiving sevelamer. Multiple regression analysis showed that variation in serum endotoxin concentrations was the strongest factor associated with IL-6 change, whereas the only variables independently associated with changes in sCD14 levels were the variations in serum IL-6 and endotoxin concentrations. CONCLUSIONS: Administration of the noncalcium phosphate binder sevelamer to maintenance HD patients is associated with a significant decrease in hs-CRP, IL-6, serum endotoxin levels and sCD14 concentrations.
RCT Entities:
BACKGROUND AND OBJECTIVES:Hyperphosphatemia and subclinical endotoxemia are important sources of inflammation in HD. Proinflammatory cytokines are strong correlates of soluble CD14 (sCD14) concentrations, an independent predictor of mortality in this population. We evaluated the effects of calcium acetate and sevelamer hydrochloride on serum inflammatory profile, endotoxin concentrations, and sCD14 levels in HDpatients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Prospective, randomized, open-label, parallel design trial. Fifty-nine stable HDpatients, 30 receiving sevelamer, and 29 receiving calcium acetate were evaluated. Serum levels of inflammatory parameters (high-sensitivity C-reactive protein [hs-CRP], TNF-α, interleukin (IL)-1, -6, -10, and -18), as well as endotoxin and sCD14 concentrations, were measured at baseline and after 3 months of therapy. RESULTS: Serum IL-6 increased in patients receiving calcium acetate, whereas hs-CRP and IL-6 significantly decreased in subjects treated with sevelamer, with IL-10 experiencing a trend to increase (P = 0.052). Serum endotoxin and sCD14 levels did not change after treatment with calcium acetate. However, these parameters decreased by 22.6% and 15.2%, respectively (P < 0.01), in patients receiving sevelamer. Multiple regression analysis showed that variation in serum endotoxin concentrations was the strongest factor associated with IL-6 change, whereas the only variables independently associated with changes in sCD14 levels were the variations in serum IL-6 and endotoxin concentrations. CONCLUSIONS: Administration of the noncalcium phosphate binder sevelamer to maintenance HDpatients is associated with a significant decrease in hs-CRP, IL-6, serum endotoxin levels and sCD14 concentrations.
Authors: J Braun; H G Asmus; H Holzer; R Brunkhorst; R Krause; W Schulz; H-H Neumayer; P Raggi; J Bommer Journal: Clin Nephrol Date: 2004-08 Impact factor: 0.975
Authors: Jacques Amar; Jean B Ruidavets; Claire Bal Dit Sollier; Vanina Bongard; Henri Boccalon; Bernard Chamontin; Ludovic Drouet; Jean Ferrières Journal: J Hypertens Date: 2003-10 Impact factor: 4.844
Authors: Geoffrey A Block; Preston S Klassen; J Michael Lazarus; Norma Ofsthun; Edmund G Lowrie; Glenn M Chertow Journal: J Am Soc Nephrol Date: 2004-08 Impact factor: 10.121
Authors: J Pugin; I D Heumann; A Tomasz; V V Kravchenko; Y Akamatsu; M Nishijima; M P Glauser; P S Tobias; R J Ulevitch Journal: Immunity Date: 1994-09 Impact factor: 31.745
Authors: Netanya G Sandler; Xinyan Zhang; Ronald J Bosch; Nicholas T Funderburg; Andrew I Choi; Janet K Robinson; Derek M Fine; Robert W Coombs; Jeffrey M Jacobson; Alan L Landay; Daniel C Douek; Randall Tressler; Sarah W Read; Cara C Wilson; Steven G Deeks; Michael M Lederman; Rajesh T Gandhi Journal: J Infect Dis Date: 2014-05-26 Impact factor: 5.226
Authors: Annabel Biruete; Kathleen M Hill Gallant; Stephen R Lindemann; Gretchen N Wiese; Neal X Chen; Sharon M Moe Journal: J Ren Nutr Date: 2019-03-04 Impact factor: 3.655
Authors: Reena Rajasuriar; Gabriela Khoury; Adeeba Kamarulzaman; Martyn A French; Paul U Cameron; Sharon R Lewin Journal: AIDS Date: 2013-05-15 Impact factor: 4.177
Authors: Mehmet Kanbay; Emine M Onal; Baris Afsar; Tuncay Dagel; Aslihan Yerlikaya; Adrian Covic; Nosratola D Vaziri Journal: Int Urol Nephrol Date: 2018-05-04 Impact factor: 2.370
Authors: Theodoros Kelesidis; Michelle A Kendall; Otto O Yang; Howard N Hodis; Judith S Currier Journal: J Infect Dis Date: 2012-10-12 Impact factor: 5.226